Brilliant Violet 421™ Streptavidin

Pricing & Availability
Other Names
SAv-Brilliant Violet 421™
Ave. Rating
4 reviews
Product Citations
publications
SAV_BV421_071911
Human peripheral blood lymphocytes were stained with biotinylated CD3 (filled histogram) or mouse IgG1 isotype control (open histogram), followed with SAV-Brilliant Violet 421™.
  • SAV_BV421_071911
    Human peripheral blood lymphocytes were stained with biotinylated CD3 (filled histogram) or mouse IgG1 isotype control (open histogram), followed with SAV-Brilliant Violet 421™.
See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Avail. Save
405226 100 µl 140€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
405225 100 µg 336€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Streptavidin binds to biotin with high affinity. Streptavidin-Brilliant Violet 421™ is useful for detecting biotinylated antibodies. The excitation of Brilliant Violet 421™ by 405 nm laser light induces a fluorescence maximum emission of 421 nm.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human, Mouse, Rat, All Species
Formulation
Cat. No. 405225: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Cat. No. 405226: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
Streptavidin was conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™.
Concentration
405225 is bottled at 0.5 mg/ml.
405226 is bottled at 0.1 mg/ml.
(concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling
The solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC, ICFC - Quality tested
IF - Validated

Recommended Usage

Each lot of this Streptavidin-Brilliant Violet 421™ is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the Brilliant Violet 421™ conjugation. For immunofluorescent staining, we recommend using 405226 at dilutions ≤0.015 µg in 100 µl staining volume per million cells. For applications requiring high concentration of streptavidin reagent such as tetramer labeling, we recommend using 405225. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Streptavidin-Brilliant Violet 421™ is useful as a second step reagent for indirect immunofluorescent staining when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-Brilliant Violet 421™ is 340 kD and Streptavidin alone is 52 kD.

Additional Product Notes

View more applications data using this product in immunofluorescence microscopy and labeling tetramers in flow cytometry in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. Kim G, et al. 2013. J. Immunol. 190:1510. PubMed.
  2. Giltiay NV, Et al. 2013. J. Immunol. 191:2155. PubMed
  3. Sugiyama D, et al. 2013. PNAS. 110:17945. PubMed
  4. Scally SW, et al. 2013. J. Exp Med. 210:2569. PubMed
  5. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  6. Higdon LE, et al. 2014. PNAS. 111:5652. PubMed
  7. Friedman RS, et al. 2014. PNAS. 111:9223. PubMed
  8. van de Weijer ML, et al. 2014. Nat Commun. 5:3832. PubMed
  9. Mise-Omata S, et al. 2014. Int Immunol. PubMed
  10. Choo JA, et al. 2014. J Virol. 88:10613. PubMed
  11. Xing YL, et al. 2014. J Neurosci. 34:14128. PubMed
  12. Luetke-Eversloh M, et al. 2014. PLoS Pathog. 10:1004441. PubMed
  13. Poh Cm, et al. 2014. Infect Immun. 82:4854. PubMed
  14. Cabrera-Perez J, et al. 2015. J Immunol. 194:1609. PubMed
  15. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  16. Krishnaswamy JK, et al. 2015. PNAS. 112:3056. PubMed
  17. Rampuria P, et al. 2015. Int Immunol. 27:253. PubMed
Product Citations
  1. Kim G, et al. 2013. J Immunol. 190:1510. PubMed
  2. Giltiay N, et al. 2013. J Immunol. 191:2155. PubMed
  3. Sugiyama D, et al. 2013. Proc Natl Acad Sci U S A. 110:17945. PubMed
  4. Scally S, et al. 2013. J Exp Med. 210:2569. PubMed
  5. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  6. Higdon L, et al. 2014. Proc Natl Acad Sci U S A. 111:5652. PubMed
  7. Claudepierre M, et al. 2014. J Virol. 88:5242. PubMed
  8. Friedman R, et al. 2014. Proc Natl Acad Sci U S A. 111:9223. PubMed
  9. Weijer M, et al. 2014. Nat Commun. 5:3832. PubMed
  10. Mise-Omata S, et al. 2014. Int Immunol. 26:607. PubMed
  11. Choo J, et al. 2014. J Virol. 88:10613. PubMed
  12. Xing Y, et al. 2014. J Neurosci. 34:14128. PubMed
  13. Luetke-Eversloh M, et al. 2014. PLoS Pathog. 10:1004441. PubMed
  14. Poh C, et al. 2014. Infect Immun . 82:4854. PubMed
  15. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  16. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  17. Krishnaswamy J, et al. 2015. Proc Natl Acad Sci U S A. 112:3056. PubMed
  18. Lang P 2015. Int Immunol. 27:253. PubMed
  19. Liu B, et al. 2015. J Immunol. 194:3583. PubMed
  20. Sanjo H, et al. 2015. PLoS One. 10: 0128761. PubMed
  21. Tsuzuki S, et al. 2015. Int Immunol. 10.1093/intimm/dxv058. PubMed
  22. Cameron G, et al. 2015. J Immunol. 195: 4604 - 4614. PubMed
  23. Trivedi S, et al. 2015. Vaccine. 33: 7315-7327. PubMed
  24. Salzberger W, et al. 2015. PLoS One. 10: 0145324. PubMed
  25. Cuenca M, et al. 2016. J Immunol. 196: 726 - 737. PubMed
  26. Elayeb R, et al. 2016. Haematologica. 101: 209 - 218. PubMed
  27. Younis R, et al. 2016. J Immunol. 196: 1419 - 1429. PubMed
  28. Xu Z, et al. 2016. Nat Commun. 7:10728. PubMed
  29. Sei J, et al. 2016. PLoS One. 11: 0152192. PubMed
  30. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  31. Li H, et al. 2016. J Immunol. 196: 4064 - 4074. PubMed
  32. Bähr A, et al. 2016. PLoS One. 11: 0155676. PubMed
  33. Takizawa F, et al. 2016. J Immunol. 196: 4522 - 4535. PubMed
  34. Yang E, et al. 2016. J Immunol. 197: 934 - 941. PubMed
  35. Im S, et al. 2016. Nature. 537:417-421. PubMed
  36. Koay H, et al. 2016. Nat Immunol. 10.1038/ni.3565. PubMed
  37. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  38. Sage P, et al. 2016. Nat Immunol. 17:1436-1446. PubMed
  39. Zhu L, et al. 2016. J Cell Sci. 129: 4238 - 4251. PubMed
  40. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
  41. Rowan A, et al. 2016. PLoS Pathog. 12:e1006030. PubMed
  42. Roberts E, et al. 2016. PLoS One. 11:e0168488. PubMed
  43. Lundell A, et al. 2017. Sci Rep. 7:39904. PubMed
  44. Hayashi M, et al. 2017. EBioMedicine. 15:127-136. PubMed
  45. An X, et al. 2017. PLoS One.. 10.1371/journal.pone.0181904. PubMed
  46. Mitra T, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.035. PubMed
  47. Angkasekwinai P, et al. 2017. PLoS One. 10.1371/journal.pone.0184684. PubMed
  48. Petursdottir D, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01699. PubMed
  49. Taguchi A, et al. 2017. Cell Stem Cell. 21:730. PubMed
  50. Miura M, et al. 2019. Wellcome Open Res. 3:105. PubMed
  51. Wilmore JR, et al. 2018. Cell Host Microbe. 23:302. PubMed
  52. Zhao M, et al. 2019. Cell Rep. 26:652. PubMed
  53. Krishack PA, et al. 2019. JCI Insight. 4:6. PubMed
  54. Cirelli KM, et al. 2019. Cell. 177:1153. PubMed
  55. Xu L, et al. 2017. Immunity. 47:538. PubMed
Publication Library

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Go To Top Version: 7    Revision Date: 06.18.2019

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

Login / Register
Forgot your password? Reset password?
Create an Account